Rural ACO consortium expands membership

 

The National Rural Accountable Care Consortium has brought on board five additional accountable care organizations (ACOs) for 2015.

To date, 52 entities, including 28 rural and critical access hospitals, 42 rural health clinics, 12 federally qualified health centers and 9 private physician practices in 30 rural health systems are part of the consortium, which helps them participate in the Medicare Shared Savings Program. Specifically, the consortium provides services including claims data access and analysis, evidence-based medicine leadership, care coordination coaching and the governance, legal and compliance services to members.

In almost all cases, the rural hospital sponsors the program and invites local providers to join for free. So far, hospitals’ annual revenue ranged from $5 million to $758 million per year, and they all included employed or contracted physicians, only one applicant had enough beneficiaries to form its own ACO, according to the consortium.

"The consortium's unique model of collaboration is the first of its kind to enable rural providers to receive higher reimbursement for improving the care they deliver," said Tim Putnam, CEO of Margaret Mary Hospital and chair of the board for the first National Rural ACO, in a statement. "We can access the same type of powerful data, waivers and programs that urban ACOs can for about the same cost as it would be to hire one person to figure out how to get into the program."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.